Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

Opis bibliograficzny
Główni autorzy:	Maymona G. Abdelmagid, Aref Al-Kali, Kebede H. Begna, William J. Hogan, Mark R. Litzow, Farah Fleti, Abhishek A. Mangaonkar, Mrinal S. Patnaik, Michelle A. Elliott, Hassan Alkhateeb, Min Shi, Matthew T. Howard, Kaaren K. Reichard, Rhett P. Ketterling, Mithun Shah, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Format:	Artykuł
Język:	English
Wydane:	Ferrata Storti Foundation 2023-02-01
Seria:	Haematologica
Dostęp online:	https://haematologica.org/article/view/10989

Podobne zapisy

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
od: Naseema Gangat, i wsp.
Wydane: (2023-01-01)

Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
od: Ayalew Tefferi, i wsp.
Wydane: (2024-03-01)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
od: Abhishek A. Mangaonkar, i wsp.
Wydane: (2022-02-01)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
od: Rimal Ilyas, i wsp.
Wydane: (2023-02-01)

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
od: Terra L. Lasho, i wsp.
Wydane: (2018-02-01)

Prognostic impact of <i>SF3B1</i> mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases
od: Faiqa Farrukh, i wsp.
Wydane: (2024-03-01)

<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
od: Abhishek A. Mangaonkar, i wsp.
Wydane: (2022-02-01)

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
od: Ayalew Tefferi, i wsp.
Wydane: (2023-07-01)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
od: Naseema Gangat, i wsp.
Wydane: (2022-06-01)

Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases
od: Maymona G. Abdelmagid, i wsp.
Wydane: (2022-07-01)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
od: Ayalew Tefferi, i wsp.
Wydane: (2022-06-01)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm
od: Naseema Gangat, i wsp.
Wydane: (2022-12-01)

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
od: Ayalew Tefferi, i wsp.
Wydane: (2023-03-01)

Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine
od: Naseema Gangat, i wsp.
Wydane: (2023-11-01)

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
od: Mostafa Abdallah, i wsp.
Wydane: (2024-03-01)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
od: Naseema Gangat, i wsp.
Wydane: (2023-03-01)

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation
od: Mrinal M. Patnaik, i wsp.
Wydane: (2019-06-01)

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
od: Ayalew Tefferi, i wsp.
Wydane: (2022-09-01)

Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases
od: Saubia Fathima, i wsp.
Wydane: (2025-03-01)

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
od: Isla M. Johnson, i wsp.
Wydane: (2025-02-01)

Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia
od: Naseema Gangat, i wsp.
Wydane: (2023-08-01)

One thousand patients with essential thrombocythemia: the Mayo Clinic experience
od: Naseema Gangat, i wsp.
Wydane: (2024-01-01)

Targeted deep sequencing in primary myelofibrosis
od: Ayalew Tefferi, i wsp.
Wydane: (2016-12-01)

Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases
od: Naseema Gangat, i wsp.
Wydane: (2022-03-01)

Erythrocytosis associated with <i>EPAS1</i>(<i>HIF2A</i>), <i>EGLN1</i>(<i>PHD2</i>), <i>VHL, EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience
od: Naseema Gangat, i wsp.
Wydane: (2022-02-01)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
od: Evandro D. Bezerra, i wsp.
Wydane: (2021-03-01)

Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
od: Maymona G. Abdelmagid, i wsp.
Wydane: (2023-08-01)

Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
od: Mostafa Abdallah, i wsp.
Wydane: (2023-03-01)

Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases
od: Kaaren K. Reichard, i wsp.
Wydane: (2022-11-01)

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
od: Nickolas Steinauer, i wsp.
Wydane: (2024-03-01)

Sodium-glucose co-transporter-2 inhibitor treatment-associated changes in hemoglobin level in anemic patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
od: Ali Alsugair, i wsp.
Wydane: (2025-01-01)

Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels
od: Ayalew Tefferi, i wsp.
Wydane: (2018-08-01)

Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience
od: Ahmad Nanaa, i wsp.
Wydane: (2021-06-01)

P544: MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL IN TREATMENT-NAÏVE PATIENTS WITH ACUTE MYELOID LEUKEMIA FOLLOWING VENETOCLAX AND HYPOMETHYLATING AGENTS
od: I. Johnson, i wsp.
Wydane: (2022-06-01)

To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia
od: Naseema Gangat, i wsp.
Wydane: (2022-04-01)

Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
od: Naseema Gangat, i wsp.
Wydane: (2020-11-01)

Mayo Clinic experience with 1123 adults with acute myeloid leukemia
od: Kebede H. Begna, i wsp.
Wydane: (2021-03-01)

Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms
od: Mithun Vinod Shah, i wsp.
Wydane: (2022-07-01)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
od: Ahmad Ghorab, i wsp.
Wydane: (2022-06-01)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
od: Maansi Joshi, i wsp.
Wydane: (2021-03-01)